-transparent.png){kind=logo}
Mitoxantrone (NSC-301739) is a synthetic amino anthraquinone DNA intercalater active in several experimental tumor systems. Thirty-three patients with advanced cancer received the drug on a daily X 5 schedule. Myelosuppression, especially leukopenia, was the dose-limiting toxicity and was reversible. Nausea and vomiting occurred sporadically. No definite hepatic, renal, or cardiac toxicities were noted. The recommended dose for phase II evaluation in solid tumor patients with little or no prior therapy is 4.2 mg/m2/day X 5. Patients with prior myelosuppressive therapy but adequate bone marrow reserve may be started at 2.6 mg/m2/day X 5.
Related Publications
M A Goldsmith, and
T Ohnuma, and
I H Jaffrey, and
E M Greenspan, and
J F Holland
June 1982,
Cancer treatment reports,
M A Goldsmith, and
T Ohnuma, and
I H Jaffrey, and
E M Greenspan, and
J F Holland
August 1990,
Investigational new drugs,
M A Goldsmith, and
T Ohnuma, and
I H Jaffrey, and
E M Greenspan, and
J F Holland
January 1990,
Cancer chemotherapy and pharmacology,
M A Goldsmith, and
T Ohnuma, and
I H Jaffrey, and
E M Greenspan, and
J F Holland
January 1982,
Cancer treatment reports,
M A Goldsmith, and
T Ohnuma, and
I H Jaffrey, and
E M Greenspan, and
J F Holland
January 1982,
Cancer treatment reports,
M A Goldsmith, and
T Ohnuma, and
I H Jaffrey, and
E M Greenspan, and
J F Holland
January 2002,
Clinical cancer research : an official journal of the American Association for Cancer Research,
M A Goldsmith, and
T Ohnuma, and
I H Jaffrey, and
E M Greenspan, and
J F Holland
January 1998,
Investigational new drugs,
M A Goldsmith, and
T Ohnuma, and
I H Jaffrey, and
E M Greenspan, and
J F Holland
April 1993,
Anti-cancer drugs,
M A Goldsmith, and
T Ohnuma, and
I H Jaffrey, and
E M Greenspan, and
J F Holland
April 1994,
Anti-cancer drugs,
M A Goldsmith, and
T Ohnuma, and
I H Jaffrey, and
E M Greenspan, and
J F Holland
December 1992,
Cancer research,
